Venture Life Share Discussion Threads

[buying] 24/9/2020 12:05

Simon Jenkins raises target from £1.15 to £1.30

[hastings] 24/9/2020 12:00

Good to see a story come together and the results this morning were excellent.Didn't manage to speak with management today, but I've popped my original article below after a chat with the CEO with some thought from today for interest.Https://martinflitton1.wixsite.com/privatepunter/post/venturing-forth-venture-life-group-24-09-2020

[qs99] 24/9/2020 10:07

with the operational leverage, why should EBITDA margins not increase from 21%?

If hits 30% then with H1 trading run rate, why should 2021 not show c.£50-60m revenues? in which case you are looking at material double digit EBITDA levels....then on to 2022 and you don't have to assume continued 80% growth rates, normalise them, you still get big numbers and cash thrown off.....DYOR etc, but if in 2-3 years time they are doing c.£20m EBIDA and multiple of say 15, why not, well you get the drift. And a divi?

DYOR but in for the long haul

[sogoesit] 24/9/2020 09:44

Have watched this a while.
Great results; bought in with a one year view to a double based on approx. 5p EPS for FY20 at 40x forward multiple. (Conservative view I think).
Current market cap of £84m at 2.5x revenue is undervalued for growth imv.

[qs99] 24/9/2020 08:51

Look forward to new broker notes....can't be long before they are pushing £10m EBITDA with plenty of cash thrown off....DYOR

[qs99] 24/9/2020 08:46

v quiet thread and v quiet share volumes given this excellent little company becoming a very successful big company hopefully!! lots more to come DYOR

[qs99] 24/9/2020 08:35

wow that is a truly great set of results

£c.7m cash and should grow or allow more aquisitions, EBITDA growing at right angles, long term deals, more in pipeline.....long long way to go with COVID study the icing IMO....DYOR

[iandippie] 24/9/2020 07:44

Just about the most positive set of results I can recall from any company ever. Truly. Up 20% today?

[farnesbarnes] 24/9/2020 07:25

These would be stunning results under normal times.

[rivaldo] 24/9/2020 07:18

Absolutely outstanding results and prospects here:



2.85p EPS in H1 is 53% of the total forecast for the year already, so it's likely that forecasts will be beaten and at the very worst matched.

I can't really see any negatives. Acquisitions are on the cards from the healthy Balance Sheet. The core business is going great guns. Look at what's happened just since the 30th June period end:

-- Boots to launch Dentyl in H2 2020
-- New Unicorn and Mermaid Dentyl editions launching in UK
-- New Dentyl toothpaste to launch in UK and internationally
-- Lloyds Pharmacy to launch newly acquired PharmaSource fungal nail products in the UK
-- Dutch retailer DA to launch new products in the Netherlands
-- Three new long-term exclusive distribution agreements signed

And this is lovely to read:

"The operational leverage developed by the Group over recent years ensures that the majority of the gross margin from incremental revenues (organic or acquired) will flow through to bottom-line profitability and cash flow. This means we expect profitability will accelerate at a higher rate than revenues."

[effortless cool] 23/9/2020 15:49

Sooner or later. Relaxed as to either.

[qs99] 23/9/2020 15:17

any views?

[qs99] 23/9/2020 14:36

Heading for new highs? When will it breach £1?

[sweepie2] 22/9/2020 13:50

Excellent appointment at Tern 26.40% owned investment, getting ready for sale or a float,new announcements coming next week

LONDON – September 22, 2020 – FundamentalVR, global leaders in using immersive technology to improve the way surgeons are trained, announces Allan May as Chairman of the company. In his role, May will lead the company’s continued growth in the United States and scale its surgical education and data insight platform, Fundamental Surgery. He will also establish a west coast office for the company.

A highly respected and established figure in Silicon Valley, May joins FundamentalVR as Chairman with decades of experience in funding, leading, and co-founding companies across biotech, Medtech, and diagnostics. He is the founder of Life Science Angels, a Bay Area early-stage investment group that has invested over $70 million in more than 70 biotech, medical device, diagnostics, and mobile health companies. He is also a Venture Partner at Medtech Convergence Fund, a $90 million seed, and early-stage venture capital fund. May will continue his work with Life Science Angels and Medtech Convergence Fund while serving as Chairman at FundamentalVR.

In 2007, May co-founded Emergent Medical Partners, a venture fund focused on early-stage medical device companies that have invested $70 million in more than 30 startups. For the last 25 years, May has served as founder, Chairman, or CEO at ten startup medical device and diagnostic companies. He has also been an investor in over 65 Medtech, biotech, and diagnostic startups. Recent companies he has co-founded include Nanostim, a developer of the first Leadless Cardiac Pacemaker, and Hyalex Surgical, a company that creates synthetic cartilage for total joints.

Established in 2015, FundamentalVR develops bespoke immersive training simulations for medical device and pharmaceutical companies and serves medical institutions and teaching hospitals through its device agnostic Fundamental Surgery platform. In 2019, it completed a series A funding round, which included participation from two leading medical institutions – Mayo Clinic, one of America’s leading centers of medical excellence, and Sana Kliniken, the third-largest hospital organization in Germany.

“We are thrilled to have Allan join FundamentalVR as Chairman and look forward to working with him during this time where we have seen interest and adoption of immersive medical technology skyrocketing during COVID,’’ said Richard Vincent, co-founder and CEO of FundamentalVR. “Allan has the experience to help us scale quickly and ensure that all surgeons, residents, and trainees around the world have access to safe and affordable training methods.”

Named as one of the best inventions of 2018 by Time magazine and 2019 winners of the SXSW Innovation Award for VR/AR & MR, Fundamental Surgery’s multimodal, multiuser platform was launched in August 2018. Its HapticVRTM modality combines virtual reality with cutting-edge haptics to create a scalable ‘flight simulator’ experience for trainees and qualified surgeons, allowing them to experience and navigate the same visuals, sounds, and feelings they would during an actual surgical procedure.

Its @HomeVR modality brings Fundamental Surgery’s educational simulations to standalone VR headsets such as Oculus Quest and HTC Vive Focus Plus. It complements the gold standard education capabilities of the HapticVRTM modality and expands the platform to provide even more flexible and cost-effective learning opportunities.

Fundamental Surgery simulations have been accredited by the American Academy of Orthopaedic Surgeons and the Royal College of Surgeons of England, allowing the use of either modality to count towards a surgeons’ ongoing professional development. It can be seen in action here.

“The combination of massive economic dislocation and social distancing brought on by COVID-19 are proving the forces needed to drive permanent change in surgical training and testing as well as the marketing and adoption of new medical devices,” commented May. “FundamentalVR are market leaders in surgical AR/VR technology. The combination of its haptics, multi-user capabilities, sophisticated use cases and applications will allow the company to dominate U.S. surgical training as it is uniquely positioned to provide the proficiency tools and metrics needed to lower the learning curve for trainee and qualified surgeons.”

[rivaldo] 22/9/2020 07:20

Remember that VLG won a contract to manufacture Alliance Pharma's Kelo-cote product - Alliance's interims this morning bring good news:

"Kelo-cote - scar prevention and treatment

We were particularly pleased with the performance of Kelo-cote, which continued to deliver growth during the first half of the year, with sales up 8% compared with the same period last year at GBP14.2m (H1 2019: GBP13.1m), primarily due to the return of demand from China during the second quarter, as local lockdown restrictions eased. In the rest of the APAC region other countries have been slower to emerge from lockdown and COVID-19 has therefore had a more sustained effect on the brand's performance. Nevertheless, we expect these regions to return strongly as lockdowns are eased, and we continue to embrace digital marketing strategies to reach the end user of the product.

During the first half of the year, we undertook further significant research amongst target users and influencers in the key global scar markets, the results from which we will be using to create new and impactful campaigns to further grow the Kelo-cote brand into 2021 and beyond. Kelo-cote was the fastest growing Top 5 Global Scar Treatment brand in 2019, according to Nicholas Hall DB6 data.

With the scar treatments market in China now growing at 29.6% per annum, Kelo-cote remains well placed to take advantage of this growth, following the conclusion of a new distribution agreement with our partner in July 2020."

[qs99] 21/9/2020 15:33

Nice to see buyers return

[farnesbarnes] 21/9/2020 13:14

It would be nice of those unthinking sheep to close their shorts though. VLG is only supposed to go up in a straight line.

[farnesbarnes] 21/9/2020 13:11

Markets are likely to be volatile for a while, at least until US elections are done, and more COVID 19 clarity.

For the sake of the economies of the world, I'm thinking (hoping) that if infection rates continue to rise, but deaths not, that herd immunity might be the way forward. And for the love of Peter, we protect the vulnerable properly.

We can't afford another blanket lockdown.

[qs99] 21/9/2020 12:09

top up time?

[bountyhunter] 17/9/2020 19:56

As I've already quoted sharw...

"Researchers will test whether or not gargling with Dentyl mouthwash can help prevent the spread of Covid-19 amid claims it could fight the virus."

"Dentyl is the only UK mouthwash brand to take part in the 12-week study.
Researchers will test whether or not gargling with Dentyl mouthwash can help prevent the spread of Covid-19 amid claims it could fight the virus."

Dentyl mouthwash is the only UK brand of mouthwash in the trial. They are NOT testing the active ingredient in isolation, they are testing it in formulation so it's excellent news that the Dentyl mouthwash formulation is part of this trial. Other products may contain CPC but not in the same formulation and are not in the clinical trial. If the trial is successful I know which mouthwash I will continue to use.



"The clinical study entitled 'The measurement of mouthwash anti-viral activity against COVID-19' (MOMA) will be commencing in August and is expected to last for 12 weeks. This is a multi-centre study and will recruit patients currently in hospital with COVID-19, commencing at Cardiff hospital."

[qs99] 17/9/2020 12:26

nice tick up, wonder why!

[sharw] 17/9/2020 10:51

They are testing the active ingredients - it is not Dentyl vs OralB it is chlorhexidine vs cetylpyridinium chloride:

"In a new Evidence Review of more than 100 articles, researchers examined ingredients commonly found in oral rinses—including ethanol, chlorhexidine, cetylpyridinium chloride, hydrogen peroxide and povidone-iodine—and weighed their potential to disrupt the lipid envelope of the SARS-CoV-2 virus and reduce viral spread. The findings, published in Function, conclude that there is an urgent need to test the effectiveness of these agents in clinical trials.

“Notably the lipid envelope does not vary when viruses mutate,” added lead author Valerie O’Donnell, PhD, of Cardiff University in Wales. “This means that if this approach can inactivate coronaviruses, the strategy—if effective—should still work the same towards new strains.”



However, as a shareholder I am very happy for VLG to get maximum publicity out of this. People don't buy things because they have read an academic paper but after reading the likes of this:

[bountyhunter] 17/9/2020 09:02

However Dentyl is the only UK brand of mouthwash in the trial. They are not testing CPC in isolation they are testing it as part of the mouthwash formulation.

"Dentyl is the only UK mouthwash brand to take part in the 12-week study.
Researchers will test whether or not gargling with Dentyl mouthwash can help prevent the spread of Covid-19 amid claims it could fight the virus."

[sharw] 15/9/2020 17:31

Don't get too excited about the Cardiff trial - it is not trying Dentyl but its ingredient cetylpyridinium chloride also found in Lemsip, Boots own brand etc:-



What VLG has got out of this is free publicity by the bucketful, which is not a bad thing!